Published on February 12, 2010 at 6:39 AM
Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that it has hired MTS Health Partners, L.P. as strategic advisor to complement and augment the company’s ongoing business development activities.
“As we are approaching announcement of initial Phase 2 results, a significant milestone in the development of our treatment for advanced Parkinson’s disease, we felt it appropriate and prudent to augment our own internal resources with MTS’s expertise and contacts in order to execute most effectively on our strategic plans.”
“Seeking strategic collaborations for the further development of our products has been and continues to be a core element of Neurologix’s business strategy,” said John Mordock, Neurologix President and Chief Executive Officer. “As we are approaching announcement of initial Phase 2 results, a significant milestone in the development of our treatment for advanced Parkinson’s disease, we felt it appropriate and prudent to augment our own internal resources with MTS’s expertise and contacts in order to execute most effectively on our strategic plans.”
SOURCE Neurologix, Inc.